论文部分内容阅读
包括蛋白酶抑制剂在内的联合抗逆转录病毒疗法大大地改变了HIV感染的治疗及其愈后。然而,由于许多病人使用受限和治疗无效,3种非蛋白酶抑制剂新药已在临床试验中广泛应用。三者分别是Glaxo Wellcom公司开发的阿巴卡韦(abacavir,商品名Ziagen),Gilead公司的阿地弗韦(ade-fovir,商品名Preveon),Du-Pont公司的依法韦司(efavirens,商品名Sustiva)。美国FDA最近已批准依法韦司用于成年人和儿童治疗HIV感染,阿巴卡韦已推荐给FDA专家委员会审批。
Combined antiretroviral therapy, including protease inhibitors, has dramatically altered the treatment of HIV infection and its prognosis. However, due to the limited use of many patients and ineffective treatment, three new non-protease inhibitor drugs have been widely used in clinical trials. They are abacavir (Ziagen) developed by Glaxo Wellcom, ade-fovir (Preveon) by Gilead, efavirens by Du-Pont Name Sustiva). FDA recently approved efavirenz for HIV infection in adults and children, and abacavir has been recommended for approval by the FDA’s Committee of Experts.